Latest / Community Health Media
T-DXd Across HER2+ Breast Cancer with Drs. Paolo Tarantino & Seth Wander
How is T-DXd reshaping the treatment pathway for HER2-positive breast cancer?
Drs. Paolo Tarantino and Seth Wander discuss the rapidly evolving role of trastuzumab deruxtecan (T-DXd) across metastatic and early-stage HER2-positive breast cancer.
From the first-line DESTINY-Breast09 data to the neoadjuvant DESTINY-Breast11 and adjuvant DESTINY-Breast05 data, they explore the new opportunities and clinical questions around treatment selection, maintenance, toxicity management, and personalization.
Topics discussed:
• How DESTINY-Breast09 is changing first-line treatment for metastatic…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.